Jean-Paul Kress, MorphoSys CEO
MorphoSys chops back again, this time cutting preclinical efforts in late-stage push
Almost exactly a year after MorphoSys $MOR signaled a retreat out of the early-stage programs picked up in its $1.7 billion Constellation buyout and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
